Comparative Pharmacology
Head-to-head clinical analysis: MOTOFEN HALF STRENGTH versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTOFEN HALF STRENGTH versus MYTESI.
MOTOFEN HALF-STRENGTH vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Motofen Half-Strength contains difenoxin (an opioid agonist) and atropine (an anticholinergic). Difenoxin inhibits gastrointestinal motility by acting on mu-opioid receptors in the gut, reducing peristalsis. Atropine discourages abuse by producing unpleasant anticholinergic effects at supratherapeutic doses.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
Adults: 1 tablet (diphenoxylate 1 mg + atropine 0.0125 mg) orally 4 times daily as needed for diarrhea, up to 8 tablets per day.
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours for diphenoxylate, 12-14 hours for atropine. Clinical context: Steady-state achieved within 1 day for diphenoxylate, 3 days for atropine.
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Renal (50% as unchanged drug and conjugates), biliary/fecal (30% as metabolites), 20% unknown.
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
Antidiarrheal
Antidiarrheal